ImmuCell Corp Files 8-K on Financials
Ticker: ICCC · Form: 8-K · Filed: Apr 9, 2024 · CIK: 811641
| Field | Detail |
|---|---|
| Company | Immucell Corp /De/ (ICCC) |
| Form Type | 8-K |
| Filed Date | Apr 9, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.10 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K, operations
Related Tickers: ICCC
TL;DR
ImmuCell just dropped its 8-K with Q1 financials - check it out!
AI Summary
On April 9, 2024, ImmuCell Corporation filed an 8-K report detailing its financial results and operations. The filing includes financial statements and exhibits, providing an update on the company's performance for the period ending April 9, 2024. The report is filed under the Securities Exchange Act of 1934.
Why It Matters
This filing provides investors with crucial, up-to-date financial information and operational details for ImmuCell Corporation, enabling informed investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing (8-K) and does not inherently introduce new risks.
Key Players & Entities
- ImmuCell Corporation (company) — Registrant
- Securities Exchange Act of 1934 (legal_document) — Governing regulation for the filing
- April 9, 2024 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing for ImmuCell Corporation?
The primary purpose is to report on the company's Results of Operations and Financial Condition, along with providing Financial Statements and Exhibits.
What is the date of the earliest event reported in this filing?
The date of the earliest event reported is April 9, 2024.
Under which act is this Current Report filed?
This Current Report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
What is ImmuCell Corporation's principal executive office address?
ImmuCell Corporation's principal executive offices are located at 56 Evergreen Drive, Portland, Maine 04103.
What is the company's telephone number?
The company's telephone number, including area code, is 207-878-2770.
Filing Stats: 544 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-04-09 16:05:13
Key Financial Figures
- $0.10 — nge on which registered Common Stock, $0.10 par value per share ICCC The NASDAQ
Filing Documents
- ea0203580-8k_immucell.htm (8-K) — 36KB
- ea020358001ex99-1_immucell.htm (EX-99.1) — 19KB
- 0001213900-24-031589.txt ( ) — 228KB
- iccc-20240409.xsd (EX-101.SCH) — 3KB
- iccc-20240409_lab.xml (EX-101.LAB) — 33KB
- iccc-20240409_pre.xml (EX-101.PRE) — 22KB
- ea0203580-8k_immucell_htm.xml (XML) — 3KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 9, 2024 ImmuCell Corporation (Exact name of registrant as specified in its charter) DE 001-12934 01-0382980 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 56 Evergreen Drive Portland , Maine 04103 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code 207 - 878-2770 (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K ling is intended to simultaneously satisfy the ling obligation of the Registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, $0.10 par value per share ICCC The NASDAQ Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 2.02. Results of Operations and Financial Condition On April 9, 2024 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited product sales for the three-month period ended March 31, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits . The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: 99.1 Press Release of ImmuCell Corporation dated April 9, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: April 9, 2024 By: /s/ Michael F. Brigham Michael F. Brigham President, Chief Executive Officer and Principal Financial Officer 2 Exhibit Index Exhibit No. Description 99.1 Press Release of ImmuCell Corporation dated April 9, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3